Syngene International will work with GSK to advance drug discovery

| By | Drug Development, GSK, R&D
0
526

Syngene International, a leading global contract research services company, announced an R&D agreement with GSK, a science-led global healthcare company. The multiyear agreement will focus on accelerating the discovery of new drug candidates using Syngene’s discovery services platforms.

As part of the agreement, Syngene will set-up a customized discovery research laboratory to support projects across several therapeutic areas. A team of Syngene scientists, will work closely with GSK’s global R&D teams on discovery research projects to identify new drug candidates with the potential to address some of the world’s most pressing healthcare needs.

Syngene started offering Discovery services to global R&D focused organizations from 1994
onwards. Over the years, the Company has consolidated its leadership position in offering integrated discovery, development and manufacturing services across small and large molecules within both the pharmaceutical and biotechnology industries.

In FY2017, Syngene serviced 293 clients including 8 of the top 10 global pharma companies as well as industry leaders in segments like biotechnology, nutrition, animal health, consumer goods and specialty chemicals.

SOURCE: syngene
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.